DeMik David E, Marinier Michael C, Glass Natalie A, Elkins Jacob M
Department of Orthopedics and Rehabilitation, University of Iowa, Iowa City, IA, USA.
Arthroplast Today. 2022 Jun 4;16:124-129. doi: 10.1016/j.artd.2022.05.001. eCollection 2022 Aug.
Body mass index (BMI) is routinely used for preoperative risk stratification; however, it does not provide a detailed assessment of body composition and intentional weight loss alone may not decrease complications. Sarcopenia-a disorder involving low muscle mass, quality, or performance-has been associated with an increased risk for postoperative complications and is treatable through nutritional supplementation or resistance training. It, counterintuitively, may occur with obesity as "sarcopenic obesity"; however, the prevalence is not widely known. The purpose of this study was to assess the prevalence of sarcopenia and sarcopenic obesity.
Patients underwent body composition assessment using multifrequency bioimpedance testing (InBody 770, InBody USA, California). They were classified as sarcopenic based on the appendicular skeletal muscle index and obese by percent body fat. Body composition parameters were compared between obesity or sarcopenia groups and traditional BMI-based obesity definitions.
A total of 219 patients underwent body composition assessment. The mean age was 62.1 years, BMI was 34.3 kg/m, and 53.8% were female. Fifty-seven (26.0%) patients were not obese or sarcopenic, 130 (59.4%) were obese not sarcopenic, 18 (8.2%) were sarcopenic nonobese, and 14 (6.4%) were sarcopenic obese. There was heterogeneity in body composition between groups. Sarcopenic patients were older than those without sarcopenia. Skeletal muscle mass, body fat mass, and appendicular skeletal muscle index increased with increasing BMI.
Sarcopenia and sarcopenic obesity were found in nearly 15% of patients. Measures of muscle quantity increased with higher BMI may influence the prevalence of sarcopenia in the morbidly obese, and these patients may require specialized criteria accounting for increased body mass.
体重指数(BMI)常用于术前风险分层;然而,它并不能提供身体成分的详细评估,而且单纯的有意减重可能不会降低并发症的发生几率。肌肉减少症——一种涉及肌肉量、质量或功能降低的病症——与术后并发症风险增加有关,可通过营养补充或抗阻训练进行治疗。与直觉相反的是,它可能与肥胖同时出现,即“肌少性肥胖”;然而,其患病率并不广为人知。本研究的目的是评估肌肉减少症和肌少性肥胖的患病率。
患者采用多频生物电阻抗测试(InBody 770,InBody美国公司,加利福尼亚州)进行身体成分评估。根据四肢骨骼肌指数将他们分类为肌肉减少症患者,根据体脂百分比将其分类为肥胖患者。比较肥胖或肌肉减少症组与基于传统BMI的肥胖定义之间的身体成分参数。
共有219名患者接受了身体成分评估。平均年龄为62.1岁,BMI为34.3kg/m²,53.8%为女性。57名(26.0%)患者既不肥胖也无肌肉减少症,130名(59.4%)患者肥胖但无肌肉减少症,18名(8.2%)患者有肌肉减少症但不肥胖,14名(6.4%)患者为肌少性肥胖。各组之间的身体成分存在异质性。有肌肉减少症的患者比没有肌肉减少症的患者年龄更大。骨骼肌质量、体脂质量和四肢骨骼肌指数随着BMI的增加而增加。
近15%的患者存在肌肉减少症和肌少性肥胖。随着BMI升高,肌肉量的测量值增加,这可能会影响病态肥胖患者中肌肉减少症的患病率,并且这些患者可能需要考虑体重增加的特殊标准。